A Phase 3 interventional study of V116 and Placebo in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 2nd registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Honduras, Puerto Rico and 1 more country
Ages 42 days–89 days · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 4 started in 2022.
This study's enrollment of 313 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 1,075 across the 10 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
43 studies in Pneumococcal Infections by Merck & Co., Inc: 1 open now, 1 under way, none of them phase 3. Of 42 finished, 40 (95%) have results posted.
Among the 43 studies in Pneumococcal Infections by Merck & Co., Inc, this one is the 29th largest by enrollment, is one of 5 that started in 2022, is one of 31 in phase 3, and was the 36th registered.
Merck & Co., Inc’s Pneumococcal Infections studies by the year they started, since 2005.
2 of the studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838000Phase 3Sanofi Pasteur, a Sanofi CompanyStudy of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | 2026-12-01 |
| NCT07348692Phase 3SanofiLot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age | 2027-06-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 43 in Pneumococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and a single IM dose of placebo on Week 8. Part B: Participants will receive a single IM dose of PCV15 between 10 to 18 months after V116.
Biological: V116 · Biological: Placebo · Biological: PCV15 - Part B
Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.
Biological: PCV15 · Biological: PPSV23
Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Also known as: Pneumococcal 21-valent Conjugate Vaccine
Saline in each 0.5 mL sterile solution
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Also known as: VAXNEUVANCE™;
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Also known as: PNEUMOVAX™23
Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Also known as: VAXNEUVANCE™
Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.
Time frame: Up to 5 days after each vaccination in Part A
Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part A
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.
Time frame: Up to 5 days after each vaccination in Part A
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A
A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed.
Time frame: Up to 194 days in Part A
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
Serotype-specific OPA to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.
Time frame: Up to 114 days
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay.
Time frame: Up to 114 days
Serotype-specific OPA Geometric Mean Fold Rises (GMFRs) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23.
Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Serotype-specific IgG GMFRs Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23
Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Percentage of Participants With a >=4-fold Rise in OPA Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination with V116 and PCV15 + PPSV23
Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Percentage of Participants With a >=4-fold Rise in IgG Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex ECL assay. The percentage of participants who had ≥4-fold rise in IgG concentration was calculated from baseline to postvaccination with V116 and PCV15 + PPSV23
Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Percentage of Participants With Solicited Injection-site AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Percentage of participants with solicited injection-site AEs from Day 1 of Part B through Day 5 postvaccination in Part B.
Time frame: Up to 5 days after vaccination in Part B
Percentage of Participants With Solicited Systemic AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia. Percentage of participants with solicited systemic AEs from Day 1 of Part B through Day 5 postvaccination in Part B
Time frame: Up to 5 days after vaccination in Part B
Percentage of Participants With Vaccine-related SAEs From Day 1 of Part B Through the Duration of Participation in Part B
A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed. Percentage of participants with vaccine-related SAEs from Day 1 of Part B through the duration of participation in Part B
Time frame: Up to 44 days after vaccination in Part B
| Milestone | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Started | 156 | 157 |
| Vaccination 1- v116 | 155 | 0 |
| Vaccination 1- pcv15 | 1 | 156 |
| Vaccination 2- placebo | 154 | 0 |
| Vaccination 2-pcv15 | 0 | 1 |
| Vaccination 2-ppsv23 | 0 | 151 |
| Completed | 152 | 152 |
| Not completed | 4 | 5 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 4 |
| Milestone | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Started | 126 | 0 |
| Completed | 125 | 0 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.
| Percentage of Participants | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Injection site erythema | 3.9 (1.4 to 8.2) | 11.0 (6.5 to 17.0) |
| Injection site pain | 50.3 (42.2 to 58.4) | 82.6 (75.7 to 88.2) |
| Injection site swelling | 7.1 (3.6 to 12.3) | 20.6 (14.6 to 27.9) |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.
| Percentage of Participants | V116 + Placebo (Part A) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Fatigue | 30.3 (23.2 to 38.2) | 34.2 (26.8 to 42.2) |
| Headache | 21.9 (15.7 to 29.3) | 19.4 (13.5 to 26.5) |
| Myalgia | 12.3 (7.5 to 18.5) | 15.5 (10.2 to 22.2) |
| Pyrexia | 1.9 (0.4 to 5.6) | 3.2 (1.1 to 7.4) |
A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed.
| Percentage of Participants | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A | 0.0 (0.0 to 2.4) | 0.0 (0.0 to 2.4) |
Serotype-specific OPA to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.
| Titers | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Serotype 3 (Shared) | 170.7 (132.5 to 220.0) | 172.0 (138.4 to 213.7) |
| Serotype 6A (Shared) | 3896.0 (2929.7 to 5181.1) | 3979.5 (3210.6 to 4932.5) |
| Serotype 7F (Shared) | 3482.3 (2815.8 to 4306.6) | 3275.6 (2658.1 to 4036.6) |
| Serotype 8 (Shared) | 1847.5 (1470.9 to 2320.6) | 2262.9 (1776.5 to 2882.5) |
| Serotype 9N (Shared) | 5763.0 (4552.8 to 7294.7) | 5970.0 (4786.9 to 7445.6) |
| Serotype 10A (Shared) | 3693.0 (2870.2 to 4751.5) | 3652.8 (2731.4 to 4885.1) |
| Serotype 11A (Shared) | 3742.5 (3050.7 to 4591.1) | 1722.3 (1277.1 to 2322.7) |
| Serotype 12F (Shared) | 2585.4 (1993.5 to 3353.0) | 2292.4 (1653.2 to 3178.8) |
| Serotype 17F (Shared) | 8698.6 (7046.1 to 10738.5) | 5886.3 (4489.8 to 7717.1) |
| Serotype 19A (Shared) | 2178.9 (1777.1 to 2671.7) | 2667.0 (2193.2 to 3243.1) |
| Serotype 20A (Shared) | 7249.1 (5854.9 to 8975.4) | 5753.3 (4634.0 to 7143.0) |
| Serotype 22F (Shared) | 3622.4 (2902.8 to 4520.4) | 3979.8 (3214.5 to 4927.1) |
| Serotype 33F (Shared) | 14642.5 (11314.9 to 18948.6) | 11864.5 (9283.8 to 15162.5) |
| Serotype 15A (Unique to V116) | 5859.0 (4684.9 to 7327.4) | 1970.5 (1555.1 to 2496.8) |
| Serotype 15C (Unique to V116) | 5613.0 (4136.7 to 7616.3) | 2438.0 (1791.5 to 3317.7) |
| Serotype 16F (Unique to V116) | 6703.0 (5494.0 to 8178.1) | 1839.0 (1474.3 to 2293.9) |
| Serotype 23A (Unique to V116) | 5053.5 (3781.3 to 6753.5) | 1674.9 (1209.9 to 2318.7) |
| Serotype 23B (Unique to V116) | 1593.8 (1182.7 to 2147.9) | 151.0 (98.1 to 232.6) |
| Serotype 24B (Unique to V116) | 3725.6 (3161.1 to 4391.0) | 567.9 (375.4 to 859.1) |
| Serotype 31 (Unique to V116) | 5699.4 (4435.1 to 7324.2) | 530.8 (364.2 to 773.7) |
| Serotype 35B (Unique to V116) | 11306.2 (9364.7 to 13650.1) | 2977.7 (2425.5 to 3655.8) |
The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay.
| μg/mL | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Serotype 3 (Shared) | 0.50 (0.43 to 0.59) | 0.58 (0.49 to 0.67) |
| Serotype 6A (Shared) | 3.79 (2.77 to 5.18) | 2.80 (2.02 to 3.89) |
| Serotype 7F (Shared) | 2.95 (2.31 to 3.77) | 1.81 (1.49 to 2.21) |
| Serotype 8 (Shared) | 7.05 (5.76 to 8.64) | 8.10 (6.66 to 9.85) |
| Serotype 9N (Shared) | 5.02 (4.01 to 6.28) | 3.36 (2.73 to 4.14) |
| Serotype 10A (Shared) | 7.15 (5.24 to 9.75) | 3.73 (2.78 to 5.00) |
| Serotype 11A (Shared) | 4.40 (3.55 to 5.45) | 2.64 (2.13 to 3.27) |
| Serotype 12F (Shared) | 1.10 (0.83 to 1.47) | 0.71 (0.51 to 0.99) |
| Serotype 17F (Shared) | 10.34 (8.24 to 12.96) | 4.43 (3.49 to 5.61) |
| Serotype 19A (Shared) | 5.96 (4.88 to 7.30) | 5.99 (4.83 to 7.43) |
| Serotype 20A (Shared) | 7.08 (5.60 to 8.95) | 4.94 (3.81 to 6.41) |
| Serotype 22F (Shared) | 3.70 (2.96 to 4.61) | 2.99 (2.40 to 3.72) |
| Serotype 33F (Shared) | 7.55 (5.90 to 9.65) | 5.56 (4.41 to 7.01) |
| Serotype 15A (Unique to V116) | 5.67 (4.37 to 7.36) | 1.02 (0.80 to 1.31) |
| Serotype 15C (Unique to V116) | 6.92 (5.15 to 9.29) | 2.68 (2.07 to 3.49) |
| Serotype 16F (Unique to V116) | 1.55 (1.23 to 1.95) | 0.21 (0.16 to 0.26) |
| Serotype 23F (Unique to V116) | 2.54 (1.85 to 3.50) | 0.41 (0.30 to 0.55) |
| Serotype 23B (Unique to V116) | 3.27 (2.51 to 4.25) | 0.99 (0.75 to 1.31) |
| Serotype 24F (Unique to V116) | 1.80 (1.25 to 2.59) | 0.17 (0.13 to 0.21) |
| Serotype 31 (Unique to V116) | 2.20 (1.78 to 2.72) | 0.25 (0.20 to 0.31) |
| Serotype 35B (Unique to V116) | 10.26 (7.96 to 13.22) | 0.90 (0.73 to 1.10) |
Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23.
| Ratio | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Serotype 3 (Shared) | 5.5 (4.3 to 7.1) | 5.3 (4.3 to 6.7) |
| Serotype 6A (Shared) | 14.3 (10.3 to 19.9) | 15.3 (11.3 to 20.7) |
| Serotype 7F (Shared) | 12.3 (9.1 to 16.3) | 7.4 (5.4 to 10.3) |
| Serotype 8 (Shared) | 11.9 (8.6 to 16.3) | 15.0 (10.4 to 21.8) |
| Serotype 9N (Shared) | 6.7 (5.0 to 8.9) | 5.9 (4.5 to 7.7) |
| Serotype 10A (Shared) | 9.4 (7.1 to 12.6) | 7.4 (5.4 to 10.2) |
| Serotype 11A (Shared) | 9.2 (6.4 to 13.4) | 3.8 (2.7 to 5.3) |
| Serotype 12F (Shared) | 57.3 (42.0 to 78.0) | 46.7 (31.4 to 69.4) |
| Serotype 17F (Shared) | 15.1 (11.2 to 20.2) | 8.5 (6.4 to 11.5) |
| Serotype 19A (Shared) | 5.0 (3.9 to 6.3) | 5.6 (4.4 to 7.2) |
| Serotype 20A (Shared) | 7.1 (5.5 to 9.2) | 4.7 (3.7 to 6.0) |
| Serotype 22F(Shared) | 19.2 (13.2 to 28.1) | 19.3 (12.7 to 29.4) |
| Serotype 33F (Shared) | 7.5 (5.6 to 10.1) | 6.8 (5.2 to 9.1) |
| Serotype 15A (Unique to V116) | 5.7 (4.2 to 7.7) | 1.4 (1.1 to 1.8) |
| Serotype 15C (Unique to V116) | 27.8 (18.7 to 41.4) | 16.3 (10.9 to 24.3) |
| Serotype 16F (Unique to V116) | 6.3 (4.8 to 8.2) | 1.7 (1.4 to 2.0) |
| Serotype 23A (Unique to V116) | 9.0 (6.0 to 13.7) | 2.8 (1.7 to 4.8) |
| Serotype 23B (Unique to V116) | 52.0 (35.7 to 75.6) | 7.2 (4.9 to 10.4) |
| Serotype 24F (Unique to V116) | 5.8 (4.0 to 8.3) | 1.0 (0.8 to 1.3) |
| Serotype 31 (Unique to V116) | 19.9 (13.8 to 28.6) | 1.5 (1.1 to 2.0) |
| Serotype 35B (Unique to V116) | 5.4 (4.3 to 6.8) | 1.3 (1.1 to 1.5) |
The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23
| Ratio | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Serotype 3 (Shared) | 3.7 (3.2 to 4.3) | 4.0 (3.4 to 4.6) |
| Serotype 6A (Shared) | 11.4 (8.8 to 14.6) | 9.2 (7.1 to 11.8) |
| Serotype 7F (Shared) | 9.1 (7.3 to 11.3) | 5.7 (4.7 to 6.8) |
| Serotype 8 (Shared) | 8.1 (6.5 to 10.1) | 10.0 (7.9 to 12.8) |
| Serotype 9N (Shared) | 10.4 (8.3 to 13.0) | 7.8 (6.3 to 9.6) |
| Serotype 10A (Shared) | 12.2 (9.7 to 15.3) | 8.2 (6.7 to 10.0) |
| Serotype 11A (Shared) | 6.6 (5.5 to 7.9) | 4.5 (3.8 to 5.3) |
| Serotype 12F (Shared) | 9.7 (7.7 to 12.4) | 6.7 (5.1 to 8.8) |
| Serotype 17F (Shared) | 13.8 (11.1 to 17.1) | 7.5 (6.2 to 9.1) |
| Serotype 19A (Shared) | 3.8 (3.2 to 4.6) | 4.8 (4.1 to 5.6) |
| Serotype 20A (Shared) | 7.3 (6.0 to 8.9) | 5.4 (4.5 to 6.5) |
| Serotype 22F (Shared) | 13.7 (10.7 to 17.5) | 10.4 (8.4 to 13.0) |
| Serotype 33F (Shared) | 8.1 (6.6 to 10.0) | 5.9 (4.9 to 7.1) |
| Serotype 15A (unique to V116) | 16.1 (13.1 to 19.9) | 2.4 (2.1 to 2.8) |
| Serotype 15C (unique to V116) | 16.6 (13.3 to 20.8) | 6.1 (5.0 to 7.5) |
| Serotype 16F (unique to V116) | 8.8 (7.3 to 10.7) | 1.4 (1.3 to 1.6) |
| Serotype 23A (unique to V116) | 15.8 (12.3 to 20.3) | 2.8 (2.3 to 3.4) |
| Serotype 23B (unique to V116) | 10.0 (8.0 to 12.6) | 3.6 (2.9 to 4.4) |
| Serotype 24F (unique to V116) | 10.9 (8.3 to 14.2) | 1.0 (0.9 to 1.1) |
| Serotype 31 (unique to V116) | 11.6 (9.6 to 14.0) | 1.4 (1.3 to 1.6) |
| Serotype 35B (unique to V116) | 11.8 (9.4 to 14.7) | 1.1 (1.0 to 1.1) |
Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination with V116 and PCV15 + PPSV23
| Percentage of Participants | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Serotype 3 (Shared) | 58.7 (49.4 to 67.6) | 61.9 (52.5 to 70.6) |
| Serotype 6A (Shared) | 73.8 (65.0 to 81.3) | 80.2 (71.7 to 87.0) |
| Serotype 7F (Shared) | 69.0 (60.3 to 76.8) | 59.2 (49.8 to 68.0) |
| Serotype 8 (Shared) | 66.9 (58.3 to 74.7) | 70.1 (61.3 to 77.9) |
| Serotype 9N (Shared) | 56.3 (47.2 to 65.2) | 57.7 (48.5 to 66.6) |
| Serotype 10A (Shared) | 62.2 (53.2 to 70.7) | 60.5 (50.9 to 69.6) |
| Serotype 11A (Shared) | 53.6 (44.5 to 62.6) | 43.6 (34.4 to 53.1) |
| Serotype 12F (Shared) | 92.2 (86.1 to 96.2) | 83.3 (75.4 to 89.5) |
| Serotype 17F (Shared) | 77.1 (68.9 to 84.0) | 64.7 (55.4 to 73.2) |
| Serotype 19A (Shared) | 49.2 (40.4 to 58.1) | 55.9 (46.8 to 64.7) |
| Serotype 20A (Shared) | 59.2 (50.3 to 67.8) | 49.2 (40.1 to 58.3) |
| Serotype 22F (Shared) | 76.0 (67.4 to 83.3) | 71.7 (62.4 to 79.8) |
| Serotype 33F (Shared) | 61.9 (52.3 to 70.9) | 58.8 (49.4 to 67.8) |
| Serotype 15A (Unique to V116) | 59.3 (49.4 to 68.6) | 21.1 (14.0 to 29.7) |
| Serotype 16F (Unique to V116) | 53.6 (44.5 to 62.6) | 16.8 (10.6 to 24.8) |
| Serotype 23A (Unique to V116) | 57.9 (47.3 to 68.0) | 32.5 (22.2 to 44.1) |
| Serotype 23B (Unique to V116) | 87.0 (79.7 to 92.4) | 50.0 (40.7 to 59.3) |
| Serotype 24F (Unique to V116) | 53.8 (43.1 to 64.4) | 7.2 (2.4 to 16.1) |
| Serotype 31 (Unique to V116) | 73.7 (65.3 to 80.9) | 16.5 (10.4 to 24.4) |
| Serotype 35B (Unique to V116) | 55.6 (46.8 to 64.2) | 5.6 (2.3 to 11.2) |
| Serotype 15C (Unique to V116) | 80.4 (71.8 to 87.3) | 71.0 (61.5 to 79.4) |
The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex ECL assay. The percentage of participants who had ≥4-fold rise in IgG concentration was calculated from baseline to postvaccination with V116 and PCV15 + PPSV23
| Percentage of participants | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) |
|---|---|---|
| Serotype 3 (Shared) | 42.3 (33.9 to 51.1) | 50.4 (41.6 to 59.2) |
| Serotype 6A (Shared) | 70.8 (62.4 to 78.3) | 68.2 (59.5 to 76.0) |
| Serotype 7F (Shared) | 70.1 (61.7 to 77.6) | 57.9 (49.0 to 66.4) |
| Serotype 8 (Shared) | 66.4 (57.9 to 74.3) | 73.7 (65.3 to 80.9) |
| Serotype 9N (Shared) | 75.2 (67.1 to 82.2) | 67.7 (59.0 to 75.5) |
| Serotype 10A (Shared) | 76.6 (68.7 to 83.4) | 68.4 (59.8 to 76.2) |
| Serotype 11A (Shared) | 66.4 (57.9 to 74.3) | 54.1 (45.3 to 62.8) |
| Serotype 12F (Shared) | 67.9 (59.4 to 75.6) | 60.2 (51.3 to 68.5) |
| Serotype 17F (Shared) | 83.9 (76.7 to 89.7) | 73.7 (65.3 to 80.9) |
| Serotype 19A (Shared) | 43.8 (35.3 to 52.5) | 58.6 (49.8 to 67.1) |
| Serotype 20A (Shared) | 67.2 (58.6 to 74.9) | 57.1 (48.3 to 65.7) |
| Serotype 22F (Shared) | 76.6 (68.7 to 83.4) | 78.9 (71.0 to 85.5) |
| Serotype 33F (Shared) | 67.9 (59.4 to 75.6) | 63.2 (54.4 to 71.4) |
| Serotype 15A (Unique to V116) | 83.9 (76.7 to 89.7) | 21.8 (15.1 to 29.8) |
| Serotype 15C (Unique to V116) | 82.5 (75.1 to 88.4) | 61.7 (52.8 to 69.9) |
| Serotype 16F (Unique to V116) | 73.7 (65.5 to 80.9) | 9.0 (4.7 to 15.2) |
| Serotype 23A (Unique to V116) | 82.5 (75.1 to 88.4) | 29.3 (21.8 to 37.8) |
| Serotype 23B (Unique to V116) | 72.3 (64.0 to 79.6) | 37.6 (29.3 to 46.4) |
| Serotype 24F (Unique to V116) | 70.1 (61.7 to 77.6) | 0.0 (0.0 to 2.7) |
| Serotype 31 (Unique to V116) | 83.2 (75.9 to 89.0) | 6.8 (3.1 to 12.5) |
| Serotype 35B (Unique to V116) | 75.9 (67.9 to 82.8) | 0.8 (0.0 to 4.1) |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Percentage of participants with solicited injection-site AEs from Day 1 of Part B through Day 5 postvaccination in Part B.
| Percentage of Participants | V116 + Placebo (Part A), PCV15 (Part B) |
|---|---|
| Injection site erythema | 3.2 (0.9 to 7.9) |
| Injection site pain | 61.9 (52.8 to 70.4) |
| Injection site swelling | 6.3 (2.8 to 12.1) |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia. Percentage of participants with solicited systemic AEs from Day 1 of Part B through Day 5 postvaccination in Part B
| Percentage of Participants | V116 + Placebo (Part A), PCV15 (Part B) |
|---|---|
| Fatigue | 22.2 (15.3 to 30.5) |
| Headache | 14.3 (8.7 to 21.6) |
| Myalgia | 11.1 (6.2 to 17.9) |
| Pyrexia | 0.8 (0.0 to 4.3) |
A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed. Percentage of participants with vaccine-related SAEs from Day 1 of Part B through the duration of participation in Part B
| Percentage of Participants | V116 + Placebo (Part A), PCV15 (Part B) |
|---|---|
| Percentage of Participants With Vaccine-related SAEs From Day 1 of Part B Through the Duration of Participation in Part B | 0.0 (0.0 to 2.9) |
Collected over Part A - Non-serious adverse events (NSAEs): Up to 30 days after each vaccination; SAEs and all-cause mortality (ACM): Up to 194 days after the first vaccination Part B - NSAEs: Up to 30 days after vaccination; SAEs and ACM: Up to 44 days after vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V116 + Placebo (Part A) | 1/156 (0.6%) | 4/155 (2.6%) | 96/155 (61.9%) |
| PCV15 + PPSV23 (Part A) | 0/157 (0%) | 6/155 (3.9%) | 136/155 (87.7%) |
| V116 + Placebo (Part A), PCV15 (Part B) | 0/126 (0%) | 1/126 (0.8%) | 82/126 (65.1%) |
| Event | V116 + Placebo (Part A) | PCV15 + PPSV23 (Part A) | V116 + Placebo (Part A), PCV15 (Part B) |
|---|---|---|---|
| PresyncopeNervous system disorders | 0/155 | 0/155 | 1/126 |
| Chest discomfortGeneral disorders | 1/155 | 0/155 | 0/126 |
| DeathGeneral disorders | 1/155 | 0/155 | 0/126 |
| Arthritis bacterialInfections and infestations | 0/155 | 1/155 | 0/126 |
| NeurosyphilisInfections and infestations | 0/155 | 1/155 | 0/126 |
| PneumoniaInfections and infestations | 0/155 | 1/155 | 0/126 |
| Ankle fractureInjury, poisoning and procedural complications | 1/155 | 0/155 | 0/126 |
| Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 1/155 | 0/126 |
| Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 1/155 | 0/126 |
| AphasiaNervous system disorders | 1/155 | 0/155 | 0/126 |
| Event | V116 + Placebo (Part A) | PCV15 + PPSV23 (Part A) | V116 + Placebo (Part A), PCV15 (Part B) |
|---|---|---|---|
| Injection site painGeneral disorders | 78/155 | 128/155 | 78/126 |
| FatigueGeneral disorders | 47/155 | 53/155 | 28/126 |
| HeadacheNervous system disorders | 38/155 | 31/155 | 19/126 |
| Injection site swellingGeneral disorders | 11/155 | 32/155 | 8/126 |
| MyalgiaMusculoskeletal and connective tissue disorders | 20/155 | 24/155 | 14/126 |
| Injection site erythemaGeneral disorders | 6/155 | 17/155 | 0/126 |
| DiarrhoeaGastrointestinal disorders | 2/155 | 9/155 | 0/126 |
| Age, Continuous(Years) | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) | Total |
|---|---|---|---|
| Mean | 44.0 ± 12.6 | 46.7 ± 12.3 | 45.3 ± 12.5 |
| Sex: Female, Male(Participants) | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) | Total |
|---|---|---|---|
| Female | 42 | 50 | 92 |
| Male | 114 | 107 | 221 |
| Ethnicity (NIH/OMB)(Participants) | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 44 | 76 |
| Not Hispanic or Latino | 124 | 112 | 236 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | V116 + Placebo (Part A), PCV15 (Part B) | PCV15 + PPSV23 (Part A) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 21 | 12 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 62 | 63 | 125 |
| White | 70 | 79 | 149 |
| More than one race | 1 | 2 | 3 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2022 to primary completion in Jul 2023, 12 months.
Results were first posted in Jul 2024, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine